Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Do what? Speculate? What are you? A judge?
Longbear. Thanks for that link. I bought a block based on that link. Funny how the price moves on just buying in 1,000 share lots. Not like the good old days where you could buy and sell and it wouldn’t move.
“One poster in ST has theorized that the company has been bought already and that it’s just waiting for the official EMA approval.”
Sorry Jess, you legally can’t do that. Or, you can do that, and risk jail time..
The link I shared earlier indicates EMA gave approval today.
COMMISSION IMPLEMENTING DECISION granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for "Lupkynis - voclosporin", a medicinal product for human use
https://ec.europa.eu/transparency/documents-register/detail?ref=C(2022)6734&lang=en
Unless i am reading this incorrectly.
the EMA decision is due out next week around the 22nd of september
approved by EMA?
https://ec.europa.eu/transparency/documents-register/detail?ref=C(2022)6734&lang=en
Not seeing any PR though...
One poster in ST has theorized that the company has been bought already and that it’s just waiting for the official EMA approval. The reasons he gave is the same reasons you just posted.If this holds true, the shorts will not be happy at all. I hope you guys are right…jmo.
The company doesn't seem to be participating in the normal fanfare for its industry this year: Biotech conferences? Insider buying? Stock options granted at considerably higher prices than the current trading price? Hmmmmm
Auphy the only thing green on my board!
showing strong on a very very bad tape! EMA decision must be coming soon.
You have a NICE graph Jess!
They don’t have the manpower and resources to do a full frontal assault on that issue. Big pharma can do it but they don’t want to let it go with a mediocre BO figure and I can understand that. They have a best in class product for an unmet medical need. The inflation/recession, Ukraine war and this pandemic kind of put the brakes on the momentum but I think they will overcome it if it’s not BO.
Cheap shares going fast now. Almost up 15 percent from capitulation.
Definitely, and Aurinia need to be shoving this in front of the faces of nephrologists and insurance companies.
I have absolutely no interest in your
investment activies, never had in fact.
Since in your kindness you indirectly
introduced me to this company in mid
July 2022 i shorted this stock @$11.89
and closed my position today @6.36
and made a nice $$$ bundle.
Thank you my friend.
I wish you good fortune in your investments!
YEAH! and I won the lottery and I'm buying a private island with a lovely view of Amalfi!
You do not know enough about this company to have made an intelligent investment decision. I expect to make more on the way up than you could have on the way down.
BTW, you seem to have taken an interest in my PURPORTED investment activity. Why? Are you taking your cue from "999"? That's a losing proposition.
Zzaatt made the year..
Closed my short position @6.36.
Thank you Zzaatt for bringing up
this company to my attention!
Thank you sir, made a bundle!
$$$$
So a little inside info
Wife ( Nephrology PA … Yale grad ) says they are increasingly concerned with the cognitive decline associated with long term steroid use .
In this case Presidone often used with LN patients.
More attention given to which LN drugs allow the fastest tapering of steriods ( AUPH … and which may allow steriods to be dropped altogether ( KZR )
Biggest problem AUPH ( Lupkynis ) faces is that it’s usually Tier 5 with a huge patient copay and the script is only for 6 mths
Kiwi
I can hear the sound of silence and it’s really deafening.
Lol, finally you admitted it BR. It took 5+ years but we both made good profit wise so all is swell and well.
Cervelo, to set the record straight, I feared the 2’s with Ariad. I didn’t fair very well with that call, fortunately. Luckily, a handsome profit there as we were absolutely saved by Takeda.
AUPH just needs to find its legs now..
Voclosporin set for EMA approval for lupus nephritis…
https://www.medwirenews.com/rheumatology/ema-approval/23324368
I got tired responding to his antics every time sp drops for even a penny.
These spineless cry babies need to grow a set or stfu and leave.
Stop crying and sell if you cant take it. The rest of us will wait for the suit to settle and the inevitable buyout to happen. You should buy cd's instead of your pathetic moaning.
after getting slammed over and over. you have to admit I was right about peter and his inability to run this company. unless of course you were hoping he would run it into the ground. Maybe BR was right when he said he feared the two's.
from the 34's down to the 6's.
calling people gadflies for stating the obvious. this was supposed to be an investment
6.70-0.52 (-7.25%)
As of 11:34AM EDT.
A new 52w/l
“There might be a number here on this board that own more than that.”
Indeed….
Sure, but not a really large purchase. Total owned is 5,300 sh. There might be a number here on this board that own more than that.
You guys think Jill is grumbling about the share price too. She is down 63% from her purchase in December 2021. Probably not...we are fine.
https://www.sec.gov/Archives/edgar/data/1600620/000162828021025130/xslF345X03/wf-form4_163960257768858.xml
Good level to consider adding or starting a position here. A lot of potential/probable catalysts forthcoming and the negative factors are already reflected by the current sp.
From a charting perspective, looking really bearish. Keeps testing support it will eventually break through. From an investor perspective prepare for another a dip.
Unfortunately I know little about what you ask. I know that looking at my insurance formulary, Lupkynis is listed as Tier 5 - non-preferred specialty drugs.
It is confusing because it says that the first script needs to be at retail and there is a 30% coinsurance. But then after that it goes to a Specialty Drug Pharmacy Program and the cost is $240 for a 31-90 day supply. Sort of doesn't make much sense to me as this is supposed to be a very expensive drug.
Recently published on July 2022; more exposure trickling out.
Published online: 11 Jul 2022.
“Key take away: voclosporin and belimumab improve renal response rates when added to standard-of-care therapy, with a statistically significant effect demonstrated at 24 weeks with voclosporin and 104 weeks with belimumab. An advantage of voclosporin over belimumab is that it also has a stabilizing effect on podocyte function that would be anticipated to reduce proteinuria and potentially preserve the histology of the kidney. This activity, together with the rapidity of the reduction in proteinuria, means that voclosporin would be the add-on therapy of choice in Class III–V proteinuric patients.”
It’s like saying take a placebo instead of aspirin/Tylenol for a toothache or headache because it’s cheap or zero cost to the patient, some rationale.
Just wondering if U know the usual patient co pay on Lupkynis…. And how often the 6 mth script , when written … is renewed?
Kiwi
Our Lupy gets a mention in this article:
https://www.yalemedicine.org/news/new-lupus-treatments
Relugolix sales ramp *during COVID pandemic*
$MYOV Orovyx/Relugolix Beautiful.https://t.co/C9fXNV6ie5 pic.twitter.com/U9vZ1vAeZr
— Sue (@Sue_S_E_N) August 26, 2022
…with the EMA decision coming soon, the Sun patent issue seems to be well timed for accumulation. We will never know if our conspiracy dreams are true…
I dreamt up a crazy conspiracy theory last night. They are going to lose the dry eye lawsuit against Sun and they know this. This is the last thing they can do to hammer the price down, collect cheap options, capitulate most retail, and Wall Street load up on shares.
Lupkynis was over a decade in the making. The FDA approval is way harder to get than any USPTO patent protection. We even have extended A2 data that proves its efficacy. They are going to win the patent and secure the 2037 protection against generics. From there it will either be bought out or they will partner with a BP like MYOV partnered with PFE.
This will all happen before the end of 2023. Wall street, the board, the ceo, will all be fully loaded with shares. The patent will be extended, a partner or buyout will be announced and the shares will moon! hopefully I don't wake up from this dream!
I haven’t owned any of this for over a year, but, wanted to cheer on the colleagues from the Ariad days that own this puppy..
U getting bullish now ?
Nrx scripts numbers are terrible and the Co is burning thru it’s cash .
I’d like to post something positive so if I see new script numbers going up I’ll post it …. But right now scripts appear to be for 6 mth max and often not renewed.
Kiwi
Candidate & Indication | Development Stage | ||||
---|---|---|---|---|---|
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market | |
VOCLOSPORINLupus Nephritis (LN) | Preclinical Phase complete | Phase 1 Phase complete | Phase 2 Phase in progress | Phase 3 Phase not started | Market Phase not started |
Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.
Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).
Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.
Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.
Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:
In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.
The list of potential product benefits includes:
LN Critical Need | Voclosporin (based on AURA Results) | |
---|---|---|
Control of Active Disease | ||
Rapid Disease Control | ||
Lower Steroid Burden | ||
Impact on Extra-renal disease | ||
Convenient Treatment Regimen |
In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s
Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.
No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |